Pharma News

Cipla Limited announced the launch of remdesivir under its brand name CIPREMI. The U.S. FDA issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc. for emergency use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. It is the only U.S. FDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection. In May, Gilead Sciences Inc. extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla’s generic version of remedisvir called CIPREMI.

A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials by the University of South Australia show the new formulation improves the drug's effectiveness by 40 per cent.

Caption : A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer. Credit : Hayley Schultz/UniSA

New research indicates that taking vitamin D supplements may help prevent a potentially serious side effect of a revolutionary form of anti-cancer therapy. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society (ACS).

 Amidst ever-increasing cases of coronavirus, efforts are being made to speed up testing of suspects of COVID-19 carriers, especially in the interior parts of the country. In one such initiative, a mobile diagnostic unit I-Lab (Infectious disease diagnostic lab) has been launched on Thursday by Dr. Harsh Vardhan, Minister of Science and Technology, Health and Family Welfare and Earth Sciences. The I-Lab is expected to help in the expansion of COVID-19 testing in remote areas.

Accurate testing is important to get out of the clutches of novel coronavirus. Steeping up efforts in this regard, the Indian Institute of Technology (IIT) Guwahati, in association with RR Animal Healthcare Ltd and Guwahati Medical College and Hospital (GMCH), has developed low-cost diagnostic kits. These are Viral Transport Media (VTM) kits, RT-PCR kits, and RNA isolation kits. Himanta Biswa Sarma, the Minister of Finance, Health and Family Welfare, Assam, launched the VTM kits.

The Central Drug Research Institute (CDRI), Lucknow, has received permission from Drug Controller General of India (DCGI) for carrying out Phase III clinical trials to test the efficacy, safety and tolerability of the antiviral drug Umifenovir. The Phase III activities will be carried out at King George's Medical University (KGMU), Dr Ram Manohar Lohia Institute of Medical Sciences (RMLIMS) and ERA's Lucknow Medical College and Hospital, Lucknow.

In the darkest parts of the world where light fails to block out the unfathomable bounty of the stars, look up. There are still fewer specks illuminating the universe than there are bacteria in the world, hidden from sight, a whole universe inside just one human gut.

New modelling research, published in The Lancet Infectious Diseases journal, suggests the coronavirus (SARS-CoV-2) that causes COVID-19 may spread more easily among people living together and family members than severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS). The estimates are the first of their kind to quantify symptomless transmission.

Caption  : Cancer cells gobble up lipids. Prostate cells are stained with Oil-Red O to detect lipid droplets. Our work shows that redistribution of lipids from prostate cancer microenvironment triggers inflammation and drives prostate cancer metastasis. Credit : Nick (Jin-Yih) Low

Johns Hopkins Kimmel Cancer Center researchers from the Department of Radiation Oncology and Molecular Radiation Sciences identified a lipid-regulating protein that conveys what the researchers describe as "superpowers" onto prostate cancer cells, causing them to aggressively spread.